(19)
(11) EP 4 096 630 A1

(12)

(43) Date of publication:
07.12.2022 Bulletin 2022/49

(21) Application number: 21708433.4

(22) Date of filing: 29.01.2021
(51) International Patent Classification (IPC): 
A61K 9/00(2006.01)
A61K 31/44(2006.01)
A61P 17/00(2006.01)
A61K 9/06(2006.01)
A61K 47/10(2017.01)
A61P 17/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/44; A61K 9/0014; A61K 9/06; A61K 47/10; A61P 17/00; A61P 17/04
 
C-Sets:
A61K 31/44, A61K 2300/00;
(86) International application number:
PCT/US2021/015740
(87) International publication number:
WO 2021/155173 (05.08.2021 Gazette 2021/31)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 31.01.2020 US 202016778845

(71) Applicant: Arcutis Biotherapeutics, Inc.
Westlake Village, CA 91361 (US)

(72) Inventors:
  • OSBORNE, David W.
    Fort Collins, Colorado 80525 (US)
  • CHAUDHURI, Bhaskar
    Westlake Village, California 91361 (US)
  • THURSTON, Archie W.
    San Diego, California 92127 (US)

(74) Representative: Weiss, Wolfgang 
Weickmann & Weickmann Patent- und Rechtsanwälte PartmbB Postfach 860 820
81635 München
81635 München (DE)

   


(54) TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF-LIFE